Cargando…

Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Wilkie, S, Brenner, MK, Taylor-Papadimitriou, J, Burchell, J, Maher, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300285/ http://dx.doi.org/10.1186/bcr1593

Ejemplares similares

Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2008)

Latest developments in MUC1 immunotherapy
por: Taylor-Papadimitriou, Joyce, et al.
Publicado: (2018)

Understanding and exploiting changes in O-linked glycosylation in breast cancer
por: Julien, S, et al.
Publicado: (2008)

Functional analysis of the breast cancer associated transcriptional repressor PLU-1/JARID1B
por: Taylor-Papadimitriou, J, et al.
Publicado: (2006)

PLU-1/Jarid1B contributes to estrogen-induced cell proliferation in the normal mammary gland and in breast cancer, and is required for embryonic survival
por: Catchpole, S, et al.
Publicado: (2010)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2006)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2008)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

Genetic engineering of pharmacologically regulated T cells, specific for breast cancer target antigens
por: Wilkie, S, et al.
Publicado: (2010)

T lymphocyte engineering with cytokine nanogels for enhanced cancer immunotherapy
por: Tang, Li, et al.
Publicado: (2015)

A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1
por: Wilkinson, R W, et al.
Publicado: (2000)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

Chitosan thermogels for local T lymphocyte delivery for cancer immunotherapy
por: Monette, Anne, et al.
Publicado: (2015)

A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells
por: Rajabzadeh, Alireza, et al.
Publicado: (2021)

The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL
por: Beatson, Richard, et al.
Publicado: (2015)

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis
por: Blixt, Ola, et al.
Publicado: (2011)

Fucosylation enhances activity of cytotoxic T lymphocytes against breast cancer
por: Qiao, Na, et al.
Publicado: (2015)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Characterization and quantification of tumor infiltrating lymphocytes in breast cancer
por: Bedri, Shahinaz, et al.
Publicado: (2014)

Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas
por: Picco, Gianfranco, et al.
Publicado: (2014)

Advances in MUC1-Mediated Breast Cancer Immunotherapy
por: Li, Zhifeng, et al.
Publicado: (2022)

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
por: Niemann, Julia, et al.
Publicado: (2019)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

Extent and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant active specific immunotherapy
por: Turksma, Annelies, et al.
Publicado: (2015)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models
por: De Meyer, Micaël, et al.
Publicado: (2013)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

MUC1 modulates the tumor immune microenvironment through the engagement of Siglec-9
por: Beatson, Richard, et al.
Publicado: (2016)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

Cancer-associated autoantibodies to MUC1 and MUC4—A blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening
por: Pedersen, Johannes W, et al.
Publicado: (2014)

Heterologous neutralization breadth persists despite B-lymphocyte dysfunction in chronic HIV-1 infection
por: Murphy, MK, et al.
Publicado: (2012)

Targeting cytotoxic T lymphocytes for cancer immunotherapy
por: Maher, J, et al.
Publicado: (2004)

Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens
por: Hanada, Ken-ichi, et al.
Publicado: (2015)

Endothelial Retargeting of AAV9 In Vivo
por: Bozoglu, Tarik, et al.
Publicado: (2022)

Development of a personalized cellular ex-vivo cbl-b silencing cancer immunotherapy
por: Lametschwandtner, Guenther, et al.
Publicado: (2014)

Mouse models for pretesting of immunotherapeutic strategies for cancer patients
por: Burchell, JM, et al.
Publicado: (2003)

Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response
por: Zizzari, Ilaria G, et al.
Publicado: (2013)

A165 FCGBP IN THE COLON IS SPATIALLY DEPENDENT ON MUC2 EXPRESSION AND IS DEGRADED IN DEXTRAN SULFATE SODIUM-INDUCED COLITIS
por: Kim, A, et al.
Publicado: (2023)

Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON
por: Hu, Zhiwei, et al.
Publicado: (2015)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b4ok4mookvkivaolkpj5c15c4p